MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Increasing Physical Activity in Parkinson’s Disease Via a Remotely Deployed Gamification Intervention

    J. Morley, K. Waddell, M. Smith, S. Wood, R. Greysen (Philadelphia, USA)

    Objective: To determine feasibility and estimate effect of a remote behavioral intervention on daily steps and motor symptoms in Veterans with PD Background: Many types…
  • 2025 International Congress

    Efficacy and safety of Rotigotine Extended-Release Microspheres in Early Parkinson’s Disease

    H. Sun, X. Dan, H. Chen, J. Feng, W. Wang, Q. Ye, Y. Liu, C. Liu, S. Chen, P. Chan (Beijing, China)

    Objective: To assess the efficacy and safety of Rotigotine extended-release microspheres (LY03003) in patients with early Parkinson's disease Background: Treatment that provides a continuous flow of…
  • 2025 International Congress

    Exploring minzasolmin effect on digital measures captured by the Verily Study Watch in a subset of the ORCHESTRA trial participants

    B. Bloem, V. Hinson, E. Goikoetxea, L. Gaetano, K. Ray, F. Ambrosetti, KC. Ho, M. Key Prato, A. Pethe, V. Ticcinelli, J. Trzebinski, S. Warma, A. Khanna, Z. Ali (Nijmegen, Netherlands)

    Objective: To investigate the progression over time and the effect of minzasolmin on digital outcomes collected in ORCHESTRA (NCT04658186). Background: Minzasolmin is an oral small…
  • 2025 International Congress

    Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years

    H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Floro, N. Abid, V. Tabar (New York, USA)

    Objective: To report the safety and clinical outcomes of bemdaneprocel in participants with Parkinson’s disease (PD) through 3 years post transplantation. Background: Bemdaneprocel is an…
  • 2025 International Congress

    Does the cerebellum compensate to enable motor learning in Parkinson’s Disease?

    PC. Iyer, BE. Fisher (Los Angeles, USA)

    Objective: To test the causal relation between cerebellar function and learning in PD. Background: Neuroimaging studies reveal that people with Parkinson’s disease (PwPD) exhibit increased…
  • 2025 International Congress

    Treatment Of Advanced Parkinson’s With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia

    B. Amlani, N. Smith (Reading, United Kingdom)

    Objective: To evaluate the effect of long-term treatment with levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion on daily time with dyskinesia in people with advanced Parkinson’s disease…
  • 2025 International Congress

    Safinamide as an Adjunct Therapy for Motor Symptoms and ON-Time Extension in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

    Objective: To evaluate the efficacy of safinamide as an adjunct therapy in improving motor symptoms and extending ON-time in patients with Parkinson’s disease (PD). Background:…
  • 2025 International Congress

    A case of Parkinson’s Disease whose Daily Levodopa/Carbidopa Intestinal Gel dose has been determined by her spouse and prevented Long-term Fluctuations

    Y. Okuma (Izunokuni, Japan)

    Objective: To present a case of Parkinson’s disease (PD) whose daily levodopa/carbidopa intestinal gel (LCIG) dose has been determined by her spouse and prevented long-term…
  • 2025 International Congress

    Mucuna pruriens for FOG in Parkinson’s disease, Do we have a solution for this trivial problem?

    M. Matta, N. Sawal, S. Singh, K. Verma, S. Sharma (Chandigarh, India)

    Objective: To study the effects of Mucuna Pruriens when administered via inhalation route,  to alleviated symptoms of Parkinson's disease most importantly freezing of gait. Background: Mucuna…
  • 2025 International Congress

    Effect of COVID-19 Pandemic on Utilization of Parkinson’s Medications in Saudi Arabia: A Repeated Cross-Sectional Study

    K. Orayj (Abha, Saudi Arabia)

    Objective: This study aims to examine the effects of the pandemic on the patterns of medication usage for Parkinson’s Disease (PD) in Saudi Arabia. Background:…
  • « Previous Page
  • 1
  • …
  • 57
  • 58
  • 59
  • 60
  • 61
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25111 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley